Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03535272 · ClinicalTrials.gov registry record · Phase 3
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
A Phase 3 study, sponsored by Centers for Disease Control and Prevention.
- Terminated
- Registry status
- Phase 3
- Development phase
- 482
- Enrollment target
NCT03535272 is a Phase 3 study that was terminated before completion, run by Centers for Disease Control and Prevention. The registered enrollment target is 482 participants.
The verdict
NCT03535272, a Phase 3 study, was terminated before completion, sponsored by Centers for Disease Control and Prevention.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 482 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate (BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial resistance (AMR) genes in fecal samples among international travelers who departed from the United States to South East Asia, South Central Asia, or Africa. Our hypotheses will be tested using a double-blinded, placebo controlled randomized clinical trial with participants from a pre-travel health clinic in the United States.
Interventions
- DRUG Placebo
- DRUG Bismuth subsalicylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 482 participants |
| Start Date | 2018-05-20 |
| Est. Completion | 2026-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03535272
The ClinicalTrials.gov registry entry for NCT03535272 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 482 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03535272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03535272 about?
NCT03535272 is a clinical study titled "Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea". The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate (BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial resistance (AMR) genes in fecal samples among international travelers who departed from the United States to South East Asia,...
What is the current status of trial NCT03535272?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 482 participants. The study started on 2018-05-20. Estimated completion is 2026-04-29.
What interventions are being tested in trial NCT03535272?
The interventions under investigation include: Placebo (DRUG), Bismuth subsalicylate (DRUG).
Who is sponsoring clinical trial NCT03535272?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.